New Study: Persistently Elevated CRP Linked to 34 Percent Higher Heart Failure Risk

C-reactive protein has been a feature of laboratory medicine for decades, and its association with cardiovascular disease is well established. But questions have remained about just how much a sustained elevation in CRP matters, separate from other risk factors, and whether the association holds across a broad population of people who already carry some degree of cardiovascular risk. A new multinational study published in September 2026 in the International Journal of Cardiology takes a fresh look at those questions with a dataset far larger than most prior analyses, and the answer is striking.

What the New Study Found

Researchers analyzed records from 64,743 adults aged 40 to 80 drawn from the TriNetX Global Research Network, a large multinational electronic health record database. All participants had at least two cardiovascular risk factors, a body mass index on record, and at least two consecutive CRP measurements that fell within the same predefined range, meaning their CRP was persistently either low or elevated rather than a single snapshot reading. This design, focusing on persistence rather than a one-time value, is an important strength of the study because it reduces the chance that a temporarily elevated reading from an acute illness or injury drives the findings.

Participants were divided into a low CRP group (0.1 to 3.0 mg/L) and an elevated CRP group (3.1 to 10.0 mg/L). The researchers used propensity-score matching to balance the two groups on key baseline characteristics including age, sex, cardiovascular risk factors, and body mass index, producing 19,547 participants in each matched group. This statistical approach helps ensure that differences in outcomes between groups reflect the CRP difference rather than other background factors.

The results were clear and consistent. After matching, participants with persistent CRP elevation had a 34 percent higher risk of developing heart failure over a maximum follow-up of ten years (hazard ratio 1.34, 95 percent confidence interval 1.22 to 1.48). The association held for both types of heart failure: heart failure with reduced ejection fraction, in which the heart pumps less forcefully, had a hazard ratio of 1.53, and heart failure with preserved ejection fraction, in which the heart is stiff rather than weak, had a hazard ratio of 1.44. All-cause mortality was 90 percent higher in the elevated CRP group (hazard ratio 1.90, 95 percent confidence interval 1.67 to 2.17). The composite outcome of heart failure or death was 49 percent higher (hazard ratio 1.49). Busti et al., 2026.

One subgroup finding is particularly interesting. Exploratory analyses showed a stronger association between elevated CRP and heart failure in participants without obesity, compared with those who were obese. The researchers noted that this may reflect the fact that obesity itself is such a powerful driver of inflammation and cardiovascular risk that the independent contribution of CRP becomes harder to separate in that population. In people of healthier body weight, persistent low-grade systemic inflammation measured by CRP may carry more of its own signal for heart disease risk.

What Persistent CRP Elevation Actually Means

The design of this study specifically required two consecutive CRP readings in the same range, which is what distinguishes it from analyses based on a single measurement. CRP can spike transiently in response to a cold, a dental infection, an injury, or other short-term immune events. That kind of elevation reflects the immune system doing exactly what it should: mounting a response and then returning to baseline. What matters for long-term cardiovascular wellness is the underlying resting level of inflammation when no acute event is disturbing the picture.

Persistent elevation above 3 mg/L suggests that the body's inflammatory tone is chronically higher than ideal. This low-grade, sustained inflammation differs from the acute kind in that it does not resolve on its own between immune challenges. Instead, it reflects a background level of inflammatory signaling driven by factors like excess adipose tissue (which secretes pro-inflammatory cytokines), metabolic dysfunction, poor sleep, physical inactivity, a diet high in ultra-processed foods, smoking, or a combination of these. Over time, this chronic inflammatory environment causes damage to the endothelium, the thin layer of cells lining blood vessels, and contributes to atherosclerosis, stiffening of the heart muscle, and ultimately impaired cardiac function.

The 3 mg/L threshold used in this study is consistent with well-established clinical guidance. Research published in the Lancet in 2010, pooling individual records from 160,309 people across 54 long-term prospective studies, found that CRP concentration was log-linearly associated with the risk of coronary heart disease, stroke, and overall mortality, with risk increasing continuously as CRP rose rather than only above a sharp cutoff. A three-fold higher CRP level was associated with a 37 percent higher adjusted risk of coronary heart disease, after accounting for conventional risk factors (Kaptoge et al., 2010). The new 2026 study builds on this foundation by specifically testing what persistent elevation looks like in a contemporary, real-world population across multiple countries.

How Inflammation Connects to Heart Failure Biology

Heart failure is not simply the result of a blocked artery. While coronary artery disease is a major contributor, heart failure can develop through several pathways, and chronic inflammation has a distinct role in most of them. The connection between CRP and heart failure is not accidental: CRP is a marker of the same inflammatory processes that damage myocardial tissue, promote fibrosis (scarring of the heart muscle), and impair the heart's ability to fill and contract efficiently over time.

Interleukin-6, or IL-6, is one of the primary cytokines that stimulates the liver to produce CRP. A 2024 narrative review in Current Atherosclerosis Reports summarized evidence from multiple large prospective studies showing that higher IL-6 is associated with increased risk of cardiovascular death, major adverse cardiovascular events, heart failure, myocardial infarction, and stroke, even after adjusting for CRP itself. The authors noted that imaging studies have also shown associations between IL-6 and progression of carotid artery plaque, suggesting that the inflammatory pathway contributes to atherosclerosis at the structural level rather than only at the level of a biomarker (Mehta et al., 2024).

The heart failure with preserved ejection fraction subtype is particularly relevant here. This form of heart failure, in which the heart is abnormally stiff rather than mechanically weak, has historically been harder to treat than its counterpart, and it is increasingly common as populations age. Chronic low-grade inflammation contributes to the myocardial fibrosis and stiffness at the center of this condition. The fact that the new Busti et al. study found elevated CRP associated with a 44 percent higher risk of this specific subtype supports the idea that inflammation is not just a bystander in the process but a genuine contributor to the structural changes that lead to disease.

CRP's role as a cardiovascular marker has deep historical roots. A landmark prospective study published in the New England Journal of Medicine in 2000 by Ridker and colleagues followed 28,263 apparently healthy postmenopausal women and found that of all the inflammatory and lipid markers tested, high-sensitivity CRP was the strongest univariate predictor of cardiovascular events. Women in the highest quartile of hsCRP had a relative risk of cardiovascular events 4.4 times that of women in the lowest quartile. In multivariate analysis, hsCRP remained independently predictive of risk even after accounting for LDL cholesterol, making it one of the few biomarkers to add meaningful information on top of standard lipid panels (Ridker et al., 2000).

What This Means for How You Monitor Your Health

The key takeaway from the new study is not that a single CRP reading above 3 mg/L is cause for alarm. A one-time elevated reading can reflect many things, including a recent illness, an injury, a stressful week, or the normal variation any biological marker shows over time. The meaningful signal is the pattern over repeated measurements: if your CRP consistently sits above 3 mg/L when you are not acutely unwell, that pattern is worth understanding and, if possible, addressing.

This is exactly the kind of longitudinal pattern that routine CRP monitoring is designed to reveal. If you measure CRP only once, you cannot distinguish a transient spike from a chronic elevation. Multiple measurements over months allow you to see your resting inflammatory baseline and to track whether lifestyle changes are moving that baseline in a healthier direction. The Busti et al. study treated persistence as the defining feature of elevated CRP risk, which aligns with the logic of monitoring trends rather than reacting to individual data points.

The lifestyle factors that drive chronic CRP elevation are the same ones implicated in cardiovascular disease more broadly. Carrying excess adipose tissue, particularly visceral fat stored around abdominal organs, is one of the strongest contributors to elevated resting CRP because fat cells secrete IL-6 and other pro-inflammatory molecules. Physical activity has consistently been shown to lower CRP across a range of populations. Diets heavy in ultra-processed foods, refined carbohydrates, and trans fats promote inflammation, while dietary patterns centered on vegetables, whole grains, legumes, fatty fish, and olive oil tend to be associated with lower CRP. Sleep deprivation and psychological stress also raise inflammatory markers. None of these relationships is simple or uniform across individuals, but they collectively point to a set of modifiable behaviors that have real effects on the inflammatory tone that CRP reflects.

Persistently elevated CRP is a signal to share with your healthcare provider, not a self-diagnosis tool. A doctor can help determine whether the elevation reflects a reversible lifestyle pattern, an underlying condition requiring clinical evaluation, or a combination. Sensa's at-home CRP test is a general wellness tool designed to give you data about your inflammatory trend over time, data that becomes more meaningful the more consistently you collect it. Think of it as an ongoing conversation between your body and your healthcare decisions, not a one-time verdict. A result above 3 mg/L consistently on multiple readings is something to bring to your doctor; a result that trends downward after starting a new exercise routine or improving your sleep tells its own useful story.

The findings of the Busti et al. study reinforce a broader principle that has been building in the cardiovascular literature for two decades. Inflammation is not just an abstract biological process: it leaves a measurable trace in the blood, that trace predicts outcomes that matter, and the gradient of risk runs continuously across the range of CRP values rather than switching on sharply above a single cutoff. Persistent low-level elevation in the 3 to 10 mg/L range, the range most likely to go unnoticed because it produces no obvious symptoms, carries real long-term risk. Monitoring that range over time, and responding to persistent elevation with the lifestyle changes that consistently reduce it, is a practical step anyone at elevated cardiovascular risk can take.

Sources

• Busti M, Monzo L, Rastogi T, et al. Persistent C-reactive protein elevation and incident heart failure in adults at increased cardiovascular risk: A multinational electronic health record study. International Journal of Cardiology. 2026;464:134934. pubmed.ncbi.nlm.nih.gov/42749086
• Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40. pubmed.ncbi.nlm.nih.gov/20031199
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine. 2000;342(12):836-43. pubmed.ncbi.nlm.nih.gov/10733371
• Mehta NN, deGoma E, Shapiro MD. IL-6 and Cardiovascular Risk: A Narrative Review. Current Atherosclerosis Reports. 2024;27(1):12. pubmed.ncbi.nlm.nih.gov/39589436

Frequently Asked Questions

What did the new study find about CRP and heart failure?

A September 2026 study published in the International Journal of Cardiology analyzed nearly 65,000 adults with at least two cardiovascular risk factors and at least two consecutive CRP measurements in the same range. Adults with persistent CRP in the elevated range (3.1 to 10.0 mg/L) had a 34 percent higher risk of developing heart failure and a 90 percent higher risk of all-cause mortality over up to ten years of follow-up, compared with adults with persistently low CRP (0.1 to 3.0 mg/L).

What CRP level is considered elevated for heart risk?

Most clinical guidelines, and the new 2026 study, use 3 mg/L as the threshold separating low from elevated CRP for cardiovascular risk purposes. CRP below 1 mg/L is considered low risk, 1 to 3 mg/L is intermediate, and above 3 mg/L (but below 10 mg/L, above which acute illness is usually the cause) signals chronic low-grade inflammation associated with higher cardiovascular risk. The key word in the new study is persistent: two or more readings above 3 mg/L are more meaningful than a single elevated result.

Can lifestyle changes lower CRP and reduce heart failure risk?

Yes. Regular physical activity, maintaining a healthy body weight, eating a diet rich in whole foods and low in ultra-processed foods, getting sufficient sleep, and reducing smoking are each associated with lower CRP. Reducing persistent CRP elevation through these changes does not guarantee a specific reduction in heart failure risk, and anyone with persistently elevated CRP should discuss the finding with their healthcare provider. But the evidence supporting lifestyle changes as a driver of lower inflammatory tone is strong across a range of study designs.

Should I test my CRP at home?

At-home CRP testing, such as the Sensa saliva-based test, is a general wellness tool that lets you track your inflammatory trend over time rather than relying on infrequent clinic visits. Tracking multiple readings over weeks and months lets you see your resting baseline and whether it is moving in the right direction after lifestyle changes. Any persistently elevated result is worth sharing with your healthcare provider for clinical interpretation. Sensa is not a medical device and is not intended to diagnose, treat, or predict specific diseases.